Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Haudum, CW; Kolesnik, E; Colantonio, C; Mursic, I; Url-Michitsch, M; Tomaschitz, A; Glantschnig, T; Hutz, B; Lind, A; Schweighofer, N; Reiter, C; Ablasser, K; Wallner, M; Tripolt, NJ; Pieske-Kraigher, E; Madl, T; Springer, A; Seidel, G; Wedrich, A; Zirlik, A; Krahn, T; Stauber, R; Pieske, B; Pieber, TR; Verheyen, N; Obermayer-Pietsch, B; Schmidt, A.
Cohort profile: 'Biomarkers of Personalised Medicine' (BioPersMed): a single-centre prospective observational cohort study in Graz/Austria to evaluate novel biomarkers in cardiovascular and metabolic diseases.
BMJ Open. 2022; 12(4):e058890 Doi: 10.1136/bmjopen-2021-058890 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Leading authors Med Uni Graz
Haudum Christoph
Obermayer-Pietsch Barbara
Co-authors Med Uni Graz
Ablasser Klemens
Colantonio Caterina
Glantschnig Theresa
Hutz Barbara
Kolesnik Ewald
Lind Alice Florentina
Madl Tobias
Mursic Ines
Pieber Thomas
Pieske Burkert Mathias
Reiter Christian
Reiter Clemens
Schmidt Albrecht
Schweighofer Natascha
Seidel Gerald
Springer Alexander
Stauber Rudolf
Tomaschitz Andreas
Tripolt Norbert
Url-Michitsch Marion
Verheyen Nicolas Dominik
Wallner Markus
Wedrich Andreas
Zirlik Andreas
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
PURPOSE: Accumulating evidence points towards a close relationship between cardiovascular, endocrine and metabolic diseases. The BioPersMed Study (Biomarkers of Personalised Medicine) is a single-centre prospective observational cohort study with repetitive examination of participants in 2-year intervals. The aim is to evaluate the predictive impact of various traditional and novel biomarkers of cardiovascular, endocrine and metabolic pathways in asymptomatic individuals at risk for cardiovascular and/or metabolic disease. PARTICIPANTS: Between 2010 and 2016, we recruited 1022 regional individuals into the study. Subjects aged 45 years or older presenting with at least one traditional cardiovascular risk factor or manifest type 2 diabetes mellitus (T2DM) were enrolled. The mean age of the participants was 57±8 years, 55% were female, 18% had T2DM, 33% suffered from arterial hypertension, 15% were smokers, 42% had hyperlipidaemia, and only 26% were at low cardiovascular risk according to the Framingham 'Systematic COronary Risk Evaluation'. FINDINGS TO DATE: Study procedures during screening and follow-up visits included a physical examination and comprehensive cardiovascular, endocrine, metabolic, ocular and laboratory workup with biobanking of blood and urine samples. The variety of assessed biomarkers allows a full phenotyping of individuals at cardiovascular and metabolic risk. Preliminary data from the cohort and relevant biomarker analyses were already used as control population for genomic studies in local and international research cooperation. FUTURE PLANS: Participants will undergo comprehensive cardiovascular, endocrine and metabolic examinations for the next decades and clinical outcomes will be adjudicated prospectively.
Find related publications in this database (using NLM MeSH Indexing)
Aged - administration & dosage
Austria - administration & dosage
Biological Specimen Banks - administration & dosage
Biomarkers - administration & dosage
Cardiovascular Diseases - diagnosis, epidemiology
Cohort Studies - administration & dosage
Diabetes Mellitus, Type 2 - diagnosis, epidemiology
Female - administration & dosage
Humans - administration & dosage
Middle Aged - administration & dosage
Precision Medicine - administration & dosage
Prospective Studies - administration & dosage
Risk Factors - administration & dosage

Find related publications in this database (Keywords)
Cardiac Epidemiology
General diabetes
General endocrinology
© Med Uni Graz • Imprint